Cooley is advising Cardioxyl Pharmaceuticals on its sale to Bristol-Myers Squibb (BMS). Under the terms of the agreement, BMS will acquire all of the issued and outstanding capital stock of Cardioxyl for upfront and near-term milestone payments of up to $300 million and potential additional milestone payments of up to $1.78 billion. The transaction is expected to close before year end.
The acquisition strengthens BMS’s focus on heart failure and gives the company full rights to Cardioxyl’s CXL-1427, a novel drug that releases nitroxyl – a molecule that has demonstrated positive effects on heart muscle and vascular function. The drug is in development for acute decompensated heart failure.
Cardioxyl, based in Chapel Hill, North Carolina, is a privately-held, clinical stage biopharmaceutical company focused on the discovery and development of new classes of safe and effective therapies for the treatment of cardiovascular disease.
The Cooley M&A team advising Cardioxyl includes head of Cooley’s M&A group Barbara Borden, Christian Plaza, Ben Beerle, Matthew Silverman, Brandon Seal and Phillip McGill.
- Cooley Advises CardioMEMS on Acquisition by St. Jude Medical
- Cooley Represents Trius Therapeutics in Acquisition by Cubist Pharmaceuticals
- Isis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
- Cooley Team Advises Excaliard Pharmaceuticals in Sale to Pfizer
- Cooley Advises Depomed in its $240 Million Diabetes Drug Sale to PDL BioPharma